Incyte at Goldman Sachs Conference: Growth Beyond Jakafi

Incyte (INCY) presented at the Goldman Sachs Healthcare Conference, outlining its strategy to offset the impending loss of exclusivity for Jakafi. The company plans to launch four new products or indications in 2024, targeting an additional $1 billion in revenue by 2029, with Opselura projected to generate $650 million in 2024 alone. Incyte is prioritizing pipeline advancement, particularly the mutant CALAR program (INCB989) for myeloproliferative neoplasms, and remains open to strategic acquisitions to bolster its portfolio; Jakafi's Q1 2024 performance showed 24% year-over-year growth, driven by demand, net price, and reduced destocking.

Analysis

Incyte Corporation, at the Goldman Sachs 46th Annual Global Healthcare Conference, outlined a comprehensive strategy to address the impending loss of exclusivity for its flagship product, Jakafi, by emphasizing robust pipeline development and portfolio diversification. The company aims to launch four new products or indications in 2024, targeting an additional $1 billion in revenue from these by 2029, alongside more than ten high-impact launches anticipated between 2026 and 2030. Jakafi demonstrated continued strength with a 24% year-over-year growth in Q1 2024, attributed to 10% demand growth, 7% net price improvement (partially due to Part D redesign benefits), and 7% from reduced destocking; full-year 2025 guidance for Jakafi projects 7% YoY growth. Opselura is a significant growth contributor, with 2024 revenue guidance of $650 million (a 28% increase), and its potential U.S. approval for pediatric atopic dermatitis in the second half of 2024 could tap into a market of 2 million children. The mutant CALAR program, particularly INCB989, shows considerable promise for myeloproliferative neoplasms, with encouraging Phase I data indicating good tolerability and potential to normalize platelet counts and reduce allele burden, targeting 35,000-40,000 essential thrombocythemia patients in the U.S. and Europe. Other key pipeline assets include POVO for hidradenitis suppurativa, with an FDA application expected in early 2026 for a potential 30,000-patient market, and a CDK2 inhibitor showing a 30% response rate in ovarian cancer. Incyte's capital allocation prioritizes advancing its internal pipeline, supplemented by opportunistic early-stage technology acquisitions.

Key Decisions for Investors

• Evaluate Incyte's strategy to mitigate Jakafi's loss of exclusivity through its diversified pipeline, targeting $1 billion in new product revenue by 2029 from 2024 launches and over ten high-impact launches between 2026-2030.
• Closely monitor upcoming clinical and regulatory catalysts, particularly full data for the mutant CALAR program (INCB989), Opselura's potential pediatric atopic dermatitis approval (expected H2 2024), POVO's FDA submission for hidradenitis suppurativa (early 2026), and progress on the CDK2 and KRAS G12D programs, as these are pivotal for future revenue generation.
• Assess the balance between near-term revenue contributions from Jakafi (24% YoY Q1 2024 growth, 7% projected 2025 growth) and Opselura ($650M 2024 guidance) against the long-term execution risks and capital deployment required for pipeline maturation in a competitive landscape.